Janney Capital analyst Ken Trbovich said that while Supernus' decision to discontinue the low-dose arm of its Phase 3 studies of SPN-810 increases the powering of the study for the high-dose arm, it removes one of two chances that existed to show a significant benefit. Also, while Supernus management said it believes enrollment can still be completed on schedule despite scrapping plans to expand enrollment by broadening recruitment to include adolescents, Trbovich thinks that is unlikely. He keeps a Neutral rating and $47 fair value estimate on Supernus shares.